安罗替尼联合不同ALK抑制剂治疗非小细胞肺癌的疗效比较

doi:10.20223/j.cnki.1000-8535.2025.02.005

摘要/Abstract

摘要： 目的评价不同间变性淋巴瘤激酶（ALK）抑制剂联合安罗替尼治疗非小细胞肺癌（NSCLC）的疗效。方法收集ALK突变阳性NSCLC患者的临床资料,筛选服用ALK抑制剂疗效不佳再加用安罗替尼的病例。根据不同的用药方案分为阿来替尼+安罗替尼,塞瑞替尼+安罗替尼和克唑替尼+安罗替尼三个组别。记录患者联合用药前最近一次的影像学检查结果,并以此为基线按Recist1.1评价疗效,以病情进展、患者死亡、停药、改变治疗方案为终点计算各组患者的无事件生存期（EFS）,收集肿瘤标志物、血常规和肝功、心功能、肾功能生化检测等指标数据,统计分析患者联合用药前后各项指标的变化。结果经筛选,共纳入49例患者的临床数据。阿来替尼+安罗替尼组有23例,疾病控制率（DCR）为86.96%;平均EFS为（10.8±3.6）个月,中位EFS为8.3个月;塞瑞替尼+安罗替尼组有14例,DCR为71.43%;平均EFS为（6.5±2.9）个月,中位EFS为5.6个月;克唑替尼+安罗替尼组有12列,DCR为66.67%;平均EFS为（7.7±3.2）个月,中位EFS为7.2个月。阿来替尼+安罗替尼组的平均EFS长于另外两组（P<0.05）。各研究组肿瘤标志物仅有CyFra21-1在克唑替尼+安罗替尼组在联合用药后升高（P<0.05）,生化检测和血常规指标在用药前后差异无统计学意义（P>0.05）。结论 ALK抑制剂与安罗替尼联用,疗效最好为阿来替尼,其次为塞瑞替尼,最后为克唑替尼。三种ALK抑制剂与安罗替尼联用后,均未导致心、肝、肾功能和血细胞损害。

关键词: 间变性淋巴瘤激酶, 阿来替尼, 塞瑞替尼, 克唑替尼, 安罗替尼

Abstract: Objective To evaluate the efficacy of different anaplastic lymphoma kinase（ALK）inhibitors combined with anlotinib in the treatment of non-small cell lung cancer（NSCLC）. Methods Clinical data of drug resistant NSCLC patients with ALK positive mutation was collected who were treated with ALK inhibitors and anlotinib synchronously．According to different regimens,three groups were set,alectinib+anlotinib,ceritinib+anlotinib,and crizotinib+anlotinib．The latest imageological examination results of the patient before the synchronous therapy was set as the baseline to evaluate the therapeutic effect according to Recist1.1．The event free survival（EFS）of each group was calculated with disease progression,patient death,treatment discontinuation and changing regimen as endpoints．Data of tumor markers,hematology test,liver function,cardiac function,renal function biochemical examination was collected and analyzed statistically before and after the combination therapy,with P<0.05 as the statistically significant difference. Results After screening,clinical data of 49 patients were collected．Twenty-three patients in the alectinib+anlotinib group,with a disease control rate（DCR） of 86.96%;mean EFS was（10.8±3.6）months,median EFS of 8.3 months;14 patients in the ceritinib+anlotinib group,with a DCR of 71.43%,mean EFS was（6.5±2.9）months,median EFS was 5.6 months;12 patients in the crizotinib+anlotinib group,with a DCR of 66.67%,mean EFS was（7.7±3.2）months,median EFS was 7.2 months．EFS of alectinib+anlotinib group was longer significantly than the other two groups（P<0.05）．Only CyFra21-1,increased significantly after the combination of crizotinib and anlotinib（P<0.05）．No statistically significant difference in biochemical test and hematology test before and after the treatment（P>0.05）． Conclusions The therapeutic effect of ALK inhibitors with anlotinib was ordered,alectinib being the most effective,followed by ceritinib and finally crizotinib．The combination of ALK inhibitors with anlotinib did not cause any abnormal results in the examination of heart,liver,kidney and blood cells．

Key words: anaplastic lymphoma kinase, alectinib, ceritinib, crizotinib, anlotinib

麦嘉怡, 陈嘉瑶, 李晓珠, 黄红兵, 刘韬, 周捷. 安罗替尼联合不同ALK抑制剂治疗非小细胞肺癌的疗效比较[J]. 广州医药, 2025, 56(2): 171-178.

MAI Jiayi, CHEN Jiayao, LI Xiaozhu, HUANG Hongbing, LIU Tao, ZHOU Jie. Comparion of the therapeutic effect of anlotinib combined with ALK inhibitors in treating non-small cell lung cancer[J]. Guangzhou Medical Journal, 2025, 56(2): 171-178.

参考文献

[1] CONDE E,ROJO F,GÓMEZ J,et al.Molecular diagnosis in non-small-cell lung cancer:Expert opinion on ALK and ROS1 testing[J].J Clin Pathol,2022,75(3):145-153.
[2] 陈波,阚连娣,叶发青,等.间变性淋巴瘤激酶在治疗非小细胞肺癌中的作用及潜在医学应用[J].中国药理学通报,2024,40(3):415-420.
[3] XIA P,ZHANG L,LI P,et al.Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers[J].J Transl Med,2021,19(1):308.
[4] COGNIGNI V,PECCI F,LUPI A,et al.The landscape of ALK-rearranged non-small cell lung cancer:A comprehensive review of clinicopathologic,genomic characteristics,and therapeutic perspectives[J].Cancers(Basel),2022,14(19):4765.
[5] KILICKAP S,OZTURK A,KARADURMUS N,et al.A multicenter,retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy[J].Medicine,2024,103(21):e37972.
[6] 何丽媛. 真实世界单中心研究:ALK融合亚型和TKI治疗模式对ALK阳性晚期NSCLC疗效和预后的影响[D].石家庄:河北医科大学,2022.
[7] WU L Y,DZIADZIUSZKO R,AHN S J,et al.Alectinib in resected ALK-positive non-small-cell lung cancer[J].N Engl J Med,2024,390(14):1265-1276.
[8] 郑晓辉,赵振营,张惠娟,等.布格替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的研究进展[J].中国药业,2023,32(9):后插1-后插4.
[9] 邢源,于文娟,颜娟.恩沙替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的研究进展[J].中国医药报,2024,21(5):36-40.
[10] 闫雨婷,孙洁雨,李茜.洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性非小细胞肺癌患者的快速卫生技术评估[J].世界临床药物,2024,45(3):317-323.
[11] PATCAS A,CHIS A F,MILITARU C F,et al.An insight into lung cancer:a comprehensive review exploring ALK TKI and mechanisms of resistance[J].Bosn J Basic Med Sci,2022,22(1):1-13.
[12] 刘禹杉,何馨彤,杜荣蓉,等.非小细胞肺癌靶向治疗药物的临床研究进展[J].药物评价研究,2021,44(2):432-439.
[13] SHEN G,ZHENG F,REN D,et al.Anlotinib:A novel multi-targeting tyrosine kinase inhibitor in clinical development[J].J Hematol Oncol,2018,11(1):120.
[14] 张国前,张书旭,吴书裕,等.基于CT影像组学的肺癌生存预后预测分析[J].现代医院,2023,23(8):1287-1292.
[15] LI H,LAI L,WU B.Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer[J].Clin Drug Investig,2020,40(2):183-189.
[16] WANG S,LOU N,LUO R,et al.Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC[J].J Transl Med,2022,20(1):248.
[17] MURCIANO-GOROFF Y R,HARADA G,DRILON A.An ascendant challenge:Central nervous system metastases in ALK+ lung cancers[J].Clin Cancer Res,2022,28(12):2477-2479.
[18] DEEKS E D.Ceritinib:A review in ALK-positive advanced NSCLC[J].Target Oncol,2016,11(5):693-700.
[19] SCHAEFER E S,BAIK C.Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer[J].Cancer Manag Res,2016(8):33-38.
[20] 何丽媛,王玉栋.ALK激酶域耐药突变的研究进展及未来应对策略[J].中国癌症杂志,2022,32(8):736-746.
[21] FUKUDA A,YOSHIDA T.Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure[J].Expert Rev Anticancer Ther,2023,23(11):1157-1167.
[22] PAN Y,DENG C,QIU Z,et al.The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer[J].Front Oncol,2021(11):713530.
[23] 徐丹,王于理,李晶,等.T790 M及COX-2在晚期非小细胞肺癌EGFR-TKI耐药中的临床研究[J].广州医药,2019,50(4):57-61.
[24] 齐泽铖,李旭,郭英伟,等.TAK1与TCF-4在非小细胞肺癌中表达及其相关性的初步研究[J].广州医药,2023,54(6):17-22.
[25] TAN AC,PAVLAKIS N.Anti-angiogenic therapy in ALK rearranged non-small cell lung cancer (NSCLC)[J].Int J Mol Sci,2022,23(16):8863.
[26] LI H,LIU J,LAN S,et al.An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy:A case report[J].Transl Lung Cancer Res,2023,12(12):2538-2549.